Coya Therapeutics Licenses Exclusive Worldwide rights to Exosome Engineering Technology (EET) from Carnegie Mellon University (CMU)
22 Setembro 2023 - 10:00AM
Business Wire
- Supported by promising data generated during the option period,
Coya has entered into an exclusive license for a next-generation
EET platform to enable engineering of exosomes with potential to
target epitope driven neurodegenerative, autoimmune and oncologic
diseases;
- Exosomes are a nanometer-sized type of extracellular vesicle
that can be shed from every cell in the body- Researchers have
attempted to harness the exosome as a drug delivery vehicle, but
techniques previously developed required the use of complex
molecular biology tools or degraded the exosome’s
functionality;
- This patented technology requires no genetic modifications,
overcomes known limitations of exosome manipulation, and also
enables tethering proteins of interest to the exosome surface and
loading cargo of interest within the exosome interior;
- Data was recently presented at the 5th Exosome Based
Therapeutic Development Summit successfully engineering a surface
protein, cytotoxic T lymphocyte associated protein 4 (CTLA-4) on to
Regulatory T cell (Treg) exosomes to increase selective targeting
to immune cells;
- EET expands Coya’s optionality for potential non-dilutive
business development and strategic partnerships with companies
seeking innovative drug and RNA delivery platforms that may be
selectively targeted to proteins or epitopes that drive
disease.
Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the
“Company”), a clinical-stage biotechnology company developing
biologics and cell therapies intended to enhance the function of
Tregs, today announced licensing of the exclusive, worldwide rights
of a proprietary Exosome Engineering Technology from CMU with
potential applications across multiple indications, including
neurodegeneration, autoimmune, and oncology.
This technology is versatile, permitting the modification of
exosomes from different biological sources while overcoming several
of the scale-up and manufacturing challenges encountered with
exosomes, including not requiring genetic manipulation. In
addition, the ability to customize the surface of the exosome with
a protein of interest while loading the interior of the exosome
with cargo opens possibilities across multiple therapeutic areas
beyond neurodegenerative diseases.
Data was recently presented at the 5th Exosome Based Therapeutic
Development Summit in Boston, MA on September 7, 2023,
demonstrating that Treg exosome membranes could be engineered to
controllably immobilize CTLA-4, a membrane surface active protein,
onto the Treg exosome surface resulting in stable CTLA-4-Treg
exosomes. CTLA-4-Treg exosomes dramatically increased targeting of,
binding to, internalization of, and uptake into immune cells
including macrophages and T cells. Previously, using the same
technology, CMU demonstrated applications in Oncology by
engineering mesenchymal derived exosomes with an immunomodulatory
apoptotic inducing protein, Fas Ligand (FAS-L).
This novel proprietary EET platform extends Coya’s pipeline
beyond Neurodegenerative disorders to include autoimmune disorders
and cancer while expanding Coya’s optionality for potential
non-dilutive business development and strategic partnerships with
companies seeking novel ways to deliver cargo/drugs in a targeted
fashion.
Fred Grossman, President and CMO said “The science behind the
technology is strong and has focused on overcoming the limitations
of exosomes. We believe this technology can shape the future of
targeted delivery of desired agents to address multiple
conditions.”
About Coya Therapeutics, Inc.
Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq:
COYA) is a clinical-stage biotechnology company developing
proprietary treatments focused on the biology and potential
therapeutic advantages of regulatory T cells (“Tregs”) to target
systemic inflammation and neuroinflammation. Dysfunctional Tregs
underlie numerous conditions including neurodegenerative,
metabolic, and autoimmune diseases, and this cellular dysfunction
may lead to a sustained inflammation and oxidative stress resulting
in lack of homeostasis of the immune system. Coya’s investigational
product candidate pipeline leverages multiple therapeutic
modalities aimed at restoring the anti-inflammatory and
immunomodulatory functions of Tregs. Coya’s lead therapeutic
programs includes Treg-enhancing biologics (COYA 300 Series product
candidates) COYA 301 and COYA 302, which are intended to enhance
Treg function and expand Treg numbers. COYA 301 is a proprietary
investigational recombinant human low dose IL-2 biologic for
subcutaneous administration intended to enhance Treg function and
expand Treg numbers in vivo, and COYA 302 is a dual-mechanism
investigational biologic combination comprised of proprietary low
dose IL-2 and CTLA-4 Ig. The low dose IL-2 is intended to enhance
anti-inflammatory regulatory T cell function and numbers while the
fusion protein CTLA-4 Ig is intended to suppress pro-inflammatory
cell function. These two mechanisms may be additive or synergistic
in suppressing inflammation. For more information about Coya,
please visit www.coyatherapeutics.com
Forward-Looking Statements
This press release contains “forward-looking” statements that
are based on our management’s beliefs and assumptions and on
information currently available to management. Forward-looking
statements include all statements other than statements of
historical fact contained in this presentation, including
information concerning our current and future financial
performance, business plans and objectives, current and future
clinical and preclinical development activities, timing and success
of our ongoing and planned clinical trials and related data, the
timing of announcements, updates and results of our clinical trials
and related data, our ability to obtain and maintain regulatory
approval, the potential therapeutic benefits and economic value of
our product candidates, competitive position, industry environment
and potential market opportunities. The words “believe,” “may,”
“will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,”
and similar expressions are intended to identify forward-looking
statements.
Forward-looking statements are subject to known and unknown
risks, uncertainties, assumptions and other factors including, but
not limited to, those related to risks associated with the impact
of COVID-19; the success, cost and timing of our product candidate
development activities and ongoing and planned clinical trials; our
plans to develop and commercialize targeted therapeutics; the
progress of patient enrollment and dosing in our preclinical or
clinical trials; the ability of our product candidates to achieve
applicable endpoints in the clinical trials; the safety profile of
our product candidates; the potential for data from our clinical
trials to support a marketing application, as well as the timing of
these events; our ability to obtain funding for our operations;
development and commercialization of our product candidates; the
timing of and our ability to obtain and maintain regulatory
approvals; the rate and degree of market acceptance and clinical
utility of our product candidates; the size and growth potential of
the markets for our product candidates, and our ability to serve
those markets; our commercialization, marketing and manufacturing
capabilities and strategy; future agreements with third parties in
connection with the commercialization of our product candidates;
our expectations regarding our ability to obtain and maintain
intellectual property protection; our dependence on third party
manufacturers; the success of competing therapies or products that
are or may become available; our ability to attract and retain key
scientific or management personnel; our ability to identify
additional product candidates with significant commercial potential
consistent with our commercial objectives; and our estimates
regarding expenses, future revenue, capital requirements and needs
for additional financing.
We have based these forward-looking statements largely on our
current expectations and projections about future events and trends
that we believe may affect our financial condition, results of
operations, business strategy, short-term and long-term business
operations and objectives, and financial needs. Moreover, we
operate in a very competitive and rapidly changing environment, and
new risks may emerge from time to time. It is not possible for our
management to predict all risks, nor can we assess the impact of
all factors on our business or the extent to which any factor, or
combination of factors, may cause actual results to differ
materially from those contained in any forward-looking statements
we may make. In light of these risks, uncertainties and
assumptions, the forward-looking events and circumstances discussed
herein may not occur and actual results could differ materially and
adversely from those anticipated or implied in the forward-looking
statements. Although our management believes that the expectations
reflected in our forward-looking statements are reasonable, we
cannot guarantee that the future results, levels of activity,
performance or events and circumstances described in the
forward-looking statements will be achieved or occur. We undertake
no obligation to publicly update any forward-looking statements,
whether written or oral, that may be made from time to time,
whether as a result of new information, future developments or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230922956379/en/
Investor Contact David Snyder
david@coyatherapeutics.com
Hayden IR James Carbonara (646)-755-7412
James@haydenir.com
Media Contact Anna Marie Imbordino
annamarie@quantum-corp.com 917-680-8765
Coya Therapeutics (NASDAQ:COYA)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Coya Therapeutics (NASDAQ:COYA)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024